Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Adaptimmune Therapeutics (473A) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Experimental: Letetresgene AutoleucelNeoplasmsPhase IIActive Not RecruitingStudy to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell LiposarcomaNov 21, 2024―
Cyclophosphamide, Fludarabine, Gsk3901961NeoplasmsPhase ITerminatedStudy of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung CancerSep 15, 2023―
Cyclophosphamide, Fludarabine, Gsk3845097NeoplasmsPhase ITerminatedStudy of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell LiposarcomaJul 05, 2023―
Afamitresgene AutoleucelSynovial Sarcoma, Osteosarcoma, Malignant Peripheral Nerve Sheath Tumor (Mpnst), Neuroblastoma (Nbl)phase1AndPhase2RecruitingSPEARHEAD-3 Pediatric StudyNov 07, 2022
Autologous Genetically Modified Adp-A2m4cd8 Cells, Autologous Genetically Modified Adp-A2m4cd8 Cells In Combination With NivolumabOvarian CancerPhase IIActive Not RecruitingADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in HLA-A2+ Subjects with MAGE-A4 Positive Ovarian Cancer (SURPASS-3)Oct 26, 2022―
Cyclophosphamide, Fludarabine, Gsk3901961, Gsk3845097, Gsk4427296NeoplasmsPhase ITerminatedMaster Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid TumorsAug 21, 2020―
Afamitresgene AutoleucelSynovial Sarcoma, Myxoid LiposarcomaPhase IIActive Not RecruitingSpearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaJul 09, 2019―
Cyclophosphamide, Fludarabine, Letetresgene AutoleucelNeoplasmsPhase IIActive Not RecruitingMaster Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid TumorsMay 10, 2019―
Autologous Genetically Modified Afpᶜ³³²t CellsHepatocellular Cancer, Afp Expressing TumorsPhase IActive Not RecruitingAFPᶜ³³²T in Advanced HCCApr 25, 2017―
Autologous Genetically Modified Mage A10ᶜ⁷⁹⁶t CellsMelanoma, Head And Neck Cancer, Urothelial Carcinoma, Bladder Urothelial CarcinomaPhase ICompletedMAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck CancersNov 07, 2016―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Adaptimmune Therapeutics Plc. (DE:473A) have in its pipeline
Adaptimmune Therapeutics DE:473A is currently developing the following drugs: Experimental: Letetresgene Autoleucel, Cyclophosphamide, Fludarabine, Gsk3901961, Cyclophosphamide, Fludarabine, Gsk3845097, Afamitresgene Autoleucel, Autologous Genetically Modified Adp-A2m4cd8 Cells, Autologous Genetically Modified Adp-A2m4cd8 Cells In Combination With Nivolumab, Cyclophosphamide, Fludarabine, Gsk3901961, Gsk3845097, Gsk4427296, Cyclophosphamide, Fludarabine, Letetresgene Autoleucel, Autologous Genetically Modified Afpᶜ³³²t Cells, Autologous Genetically Modified Mage A10ᶜ⁷⁹⁶t Cells. These drug candidates are in various stages of clinical development as the company works toward FDA approval.